We rate ASP Isotopes as a sell for retail value investors, citing price volatility, losses, high debt, and operational ...

In this issue: clinical trial challenges and developments to keep an eye on in 2025, navigating the red tape around radiopharmaceutical trials, assessing the M&A potential this year in biopharma, and ...

President Donald Trump and congressional Republicans push ahead on signature campaign promises with a flurry of actions on ...

Metalla Royalty & Streaming Ltd. ("Metalla" or the "Company") (NYSE American: MTA) (TSXV: MTA) is pleased to report the following recent developments in its royalty portfolio: ...